Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 20/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601492 | 0.86 | HRH4 (0.52) | HRH4 | |
| SCHEMBL13338285 | 0.84 | HRH4 (0.55) | HRH4 | |
| SCHEMBL13338283 | 0.84 | HRH4 (0.58) | HRH4 | |
| SCHEMBL13338279 | 0.83 | HRH4 (0.67) | HRH4 | |
| SCHEMBL602869 | 0.82 | HRH4 (1.00) | HRH4 | |
| SCHEMBL603797 | 0.82 | HRH4 (0.67) | HRH4 | |
| SCHEMBL604634 | 0.81 | HRH4 (0.84) | HRH4 | |
| SCHEMBL603265 | 0.81 | HRH4 (0.84) | HRH4 | |
| SCHEMBL601582 | 0.80 | HRH4 (0.58) | HRH4 | |
| SCHEMBL14031306 | 0.80 | HRH4 (0.82) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723527-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-25 | — | — | US | disclosed |
| US-7723359-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-25 | — | — | US | disclosed |
| US-7723359-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-25 | — | — | US | disclosed |
| US-7723526-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-25 | — | — | US | disclosed |
| US-7723526-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-25 | — | — | US | disclosed |
| US-7723527-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-25 | — | — | US | disclosed |
| US-7705149-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705149-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705143-B2 | 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-[1,4]diazepan-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; use in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions | JANSSEN PHARMACEUTICA N.V. (BG) | 2010-04-27 | — | — | US | disclosed |
| US-7705143-B2 | 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-[1,4]diazepan-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; use in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions | JANSSEN PHARMACEUTICA N.V. (BG) | 2010-04-27 | — | — | US | disclosed |
| US-20090264645-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264645-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264646-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264647-A1 | 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-piperazin-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; leukocyte recruitment inhibition, modulating H4 receptor, and treating conditions such as inflammation | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264647-A1 | 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-piperazin-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; leukocyte recruitment inhibition, modulating H4 receptor, and treating conditions such as inflammation | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090247508-A1 | Benzoimidazole Compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247508-A1 | Benzoimidazole Compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-01 | — | — | US | disclosed |
| EP-1673348-B1 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| US-7432378-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-7432378-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264646-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH4 1/4885 |
| US-20090264647-A1 | 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-piperazin-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; leukocyte recruitment inhibition, modulating H4 receptor, and treating conditions such as inflammation | HRH4, HRH3, BRD4 | HRH4 1/4885 |
| US-20090247508-A1 | Benzoimidazole Compounds | HRH4, HRH3, BRD4 | HRH4 1/4885 |
| US-20090264645-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.